scispace - formally typeset
M

Marcelo E. Bigal

Researcher at Albert Einstein College of Medicine

Publications -  323
Citations -  29068

Marcelo E. Bigal is an academic researcher from Albert Einstein College of Medicine. The author has contributed to research in topics: Migraine & Chronic Migraine. The author has an hindex of 74, co-authored 318 publications receiving 26130 citations. Previous affiliations of Marcelo E. Bigal include Tufts Medical Center & National Institute for Health Research.

Papers
More filters
Journal ArticleDOI

The International Classification of Headache Disorders, 3rd edition (beta version)

Jes Olesen, +131 more
- 01 Jul 2013 - 
TL;DR: The International Classification of Headache Disorders, 3 edition (beta version), may be reproduced freely for scientific, educational or clinical uses by institutions, societies or individuals as mentioned in this paper. But the authors require the permission of the International Headache Society.
Journal ArticleDOI

Migraine prevalence, disease burden, and the need for preventive therapy

TL;DR: The epidemiologic profile of migraine has remained stable in the United States during the past 15 years and more than one in four migraineurs are candidates for preventive therapy, and a substantial proportion of those who might benefit from prevention do not receive it.
Journal ArticleDOI

Migraine and cardiovascular disease: systematic review and meta-analysis

TL;DR: Migraine is associated with a twofold increased risk of ischaemic stroke, which is only apparent among people who have migraine with aura, and the results suggest a higher risk among women and risk was further magnified for people with migraine who were aged less than 45, smokers, and women who used oral contraceptives.
Journal ArticleDOI

Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study

TL;DR: Although symptomatic medication overuse is believed to play a major role in progression from episodic to chronic or transformed migraine (TM), population‐based longitudinal data on these agents are limited.
Journal ArticleDOI

Fremanezumab for the Preventive Treatment of Chronic Migraine

TL;DR: Fremanezumab as a preventive treatment for chronic migraine resulted in a lower frequency of headache than placebo in this 12‐week trial, and the long‐term durability and safety of fremanzumab require further study.